Palisade Bio announced FDA clearance of its Investigational New Drug application for PALI-2108, allowing the start of a global Phase 2 trial (ASCENTRA-UC) targeting moderately to severely active ulcerative colitis. The trial aims to enroll about 204 patients across North America and Europe, with enrollment beginning in the second half of 2026 and primary results expected by late 2027. PALI-2108 is a novel oral PDE4 inhibitor prodrug designed for targeted activation in the gut, showing promising Phase 1 safety and efficacy data. The company also plans to expand development into Crohn’s disease with a related trial expected to start IND submission in late 2026.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
